Bivalent rLP2086 Vaccine (Trumenba®): A Review in Active Immunization Against Invasive Meningococcal Group B Disease in Individuals Aged 10–25 Years

Prevention and control of meningococcal outbreaks: The emerging role of serogroup B meningococcal vaccines

(2015) Ernesto Oviedo-Orta et al.   VACCINE

Meningococcal Serogroup B Bivalent rLP2086 Vaccine Elicits Broad and Robust Serum Bactericidal Responses in Healthy Adolescents

(2015) Timo Vesikari et al.   Journal of the Pediatric Infectious Diseases Society

Genetic Diversity and Levels of Expression of Factor H Binding Protein among Carriage Isolates of Neisseria meningitidis

(2014) Ludovic Lemée et al.   PLoS One

The Discovery and Development of a Novel Vaccine to Protect againstNeisseria meningitidisSerogroup B Disease

(2014) Gary W Zlotnick et al.   Human Vaccines & Immunotherapeutics

Meningococcal Vaccines: Current Issues and Future Strategies

(2013) Amanda C. Cohn et al.   DRUGS

A phase 2 open-label safety and immunogenicity study of a meningococcal B bivalent rLP2086 vaccine in healthy adults

(2013) Helen S. Marshall et al.   VACCINE

Potential impact of the bivalent rLP2086 vaccine onNeisseria meningitidiscarriage and invasive serogroup B disease

(2013) Annaliesa S. Anderson et al.   Human Vaccines & Immunotherapeutics

Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial

(2012) Peter C Richmond et al.   LANCET INFECTIOUS DISEASES

A Randomized, Controlled, Phase 1/2 Trial of a Neisseria meningitidis Serogroup B Bivalent rLP2086 Vaccine in Healthy Children and Adolescents

(2012) Michael D. Nissen et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Advances with vaccination againstNeisseria meningitidis

(2012) Ray Borrow   TROPICAL MEDICINE & INTERNATIONAL HEALTH

A bivalent Neisseria meningitidis recombinant lipidated factor H binding protein vaccine in young adults: Results of a randomised, controlled, dose-escalation phase 1 trial

(2012) P.C. Richmond et al.   VACCINE

Could the multicomponent meningococcal serogroup B vaccine (4CMenB) control Neisseria meningitidis capsular group X outbreaks in Africa?

(2012) Eva Hong et al.   VACCINE

A phase 1, randomized, open-label, active-controlled trial to assess the safety of a meningococcal serogroup B bivalent rLP2086 vaccine in healthy adults

(2012) Eric Sheldon et al.   Human Vaccines & Immunotherapeutics

New frontiers in meningococcal vaccines

(2011) Annaliesa S Anderson et al.   Expert Review of Vaccines

Preclinical evidence for the potential of a bivalent fHBP vaccine to preventNeisseria meningitidisSerogroup C Disease

(2011) Shannon L. Harris et al.   Human vaccines & immunotherapeutics

Prevalence and genetic diversity of candidate vaccine antigens among invasive Neisseria meningitidis isolates in the United States

(2011) Xin Wang et al.   VACCINE

The changing and dynamic epidemiology of meningococcal disease

(2011) Scott A. Halperin et al.   VACCINE

Human antibody responses to the meningococcal factor H binding protein (LP2086) during invasive disease, colonization and carriage

(2010) Dlawer A.A. Ala’Aldeen et al.   VACCINE

Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease

(2010) Han-Qing Jiang et al.   VACCINE

Changes inNeisseria meningitidisDisease Epidemiology in the United States, 1998–2007: Implications for Prevention of Meningococcal Disease

(2009) Amanda C. Cohn et al.   CLINICAL INFECTIOUS DISEASES

Sequence Diversity of the Factor H Binding Protein Vaccine Candidate in Epidemiologically Relevant Strains of Serogroup BNeisseria meningitidis

(2009) Ellen Murphy et al.   JOURNAL OF INFECTIOUS DISEASES

Meningococcal Factor H–Binding Protein Variants Expressed by Epidemic Capsular Group A, W‐135, and X Strains from Africa

(2009) P. T. Beernink et al.   JOURNAL OF INFECTIOUS DISEASES

The modular architecture of meningococcal factor H-binding protein

(2009) P. T. Beernink et al.   MICROBIOLOGY-SGM

Neisseria meningitidis recruits factor H using protein mimicry of host carbohydrates

(2009) Muriel C. Schneider et al.   NATURE

Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis

(2009) Johan Holst et al.   VACCINE

Meningococcal protein antigens and vaccines

(2009) Ian M. Feavers et al.   VACCINE

Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease

(2009) Carl E. Frasch et al.   VACCINE

Detection of LP2086 on the cell surface of Neisseria meningitidis and its accessibility in the presence of serogroup B capsular polysaccharide

(2009) Lisa K. McNeil et al.   VACCINE

Global epidemiology of meningococcal disease

(2009) Lee H. Harrison et al.   VACCINE

Frequency of factor H-binding protein modular groups and susceptibility to cross-reactive bactericidal activity in invasive meningococcal isolates

(2009) Rolando Pajon et al.   VACCINE

Impact of Meningococcal Serogroup C Conjugate Vaccines on Carriage and Herd Immunity

(2008) Martin C. J. Maiden et al.   JOURNAL OF INFECTIOUS DISEASES

Factor H-binding protein, a unique meningococcal vaccine antigen

(2008) Mariagrazia Pizza et al.   VACCINE